New York University School Of Medicine

New York, NY

Compare ↔

$5,960,062,723

Total funding

4,249

Grants

Funding over time

peak $855.4M · FY2005–25

$1B$750M$500M$250M$0

'05

'06

'07

'08

'09

'10

'11

'12

'13

'14

'15

'16

'17

'18

'19

'20

'21

'22

'23

'24

'25

Funding mix

By agency

NIH$5,798,962,378 · 4160

CDC$109,372,777 · 58

AHRQ$48,451,625 · 22

FDA$4,954,925 · 7

SAMHSA$0 · 3

By mechanism

R01$2,865,807,684 · 1320

OT2$658,860,146 · 6

U01$354,747,698 · 84

R21$164,818,810 · 393

P01$163,097,230 · 138

P30$157,460,559 · 196

Investigators at New York University School Of Medicine

Investigator-initiated All funding

Investigatorsi

Rising Stars

First grant in the last 5 yrs

1Rebecca Florsheim$2,726,7691 gr 2Hugo Javier Aparicio$2,712,6083 gr 3Omar El-Shahawy$2,623,8682 gr 4Shane Liddelow$2,504,1983 gr 5Kenneth Stapleford$2,390,4822 gr 6David Beck$2,325,2843 gr 7Claude Steriade$2,221,2781 gr 8Ingrid G Ellen$2,075,5231 gr

Emerging Leaders

6–10 yrs in

1Anna Bershteyn$11,393,1487 gr 2Abraham Aizer Brody$10,423,2174 gr 3Hemali Phatnani$8,500,4176 gr 4Liam J Holt$8,072,8873 gr 5Jayeeta Basu$7,757,3414 gr 6Maria A Curotto De Lafaille$7,568,0064 gr 7Katharina Schultebraucks$6,916,5062 gr 8Omonigho A Michael Bubu$6,406,7032 gr

All-Time

Most funded here, all years

1Daniel C. Javitt$32,383,43117 gr 2Iannis Aifantis$28,837,06418 gr 3Dan R Littman$27,957,10913 gr 4Richard W Tsien$27,436,0199 gr 5Ira Jay Goldberg$26,955,13610 gr 6Josef Coresh$26,377,2199 gr 7Robert Schneider$23,756,2979 gr 8Einar M Sigurdsson$23,612,32810 gr

Largest grants

OTA-21-015A Post-Acute Sequelae of SARS-CoV-2 Infection Initiative: NYU Langone Health Clinical Science Core, Data Resource Core, and PASC Biorepository Core$448,283,318

OT2 · FY2021 · HL

OTA-21-015A Post-Acute Sequelae of SARS-CoV-2 Infection Initiative: NYU Langone Health Clinical Science Core, Data Resource Core, and PASC Biorepository Core$109,438,442

OT2 · FY2024 · HL

OTA-21-015A Post-Acute Sequelae of SARS-CoV-2 Infection Initiative: NYU Langone Health Clinical Science Core, Data Resource Core, and PASC Biorepository Core$59,963,139

OT2 · FY2023 · HL

OTA-21-015A Post-Acute Sequelae of SARS-CoV-2 Infection Initiative: NYU Langone Health Clinical Science Core, Data Resource Core, and PASC Biorepository Core$33,203,136

OT2 · FY2022 · HL

Research Facilities Restoration Program New Science Building$29,376,655

C06 · FY2014 · OD

Clinical and Translational Science Award$20,343,524

UL1 · FY2021 · TR

Research Facilities Restoration Program Alexandria Center for Life Sciences-West$19,477,294

C06 · FY2014 · OD

The Ischemia Trial - CCC$18,967,704

U01 · FY2017 · HL

Long-acting buprenorphine vs. naltrexone opioid treatments in CJS-involved adults$17,761,674

U01 · FY2019 · DA

ED-LEAD: Emergency Departments LEading the transformation of Alzheimer's and Dementia care$17,240,889

U19 · FY2024 · AG

ED-LEAD: Emergency Departments LEading the transformation of Alzheimer's and Dementia care$16,848,854

U19 · FY2025 · AG

The Ischemia Trial - CCC$16,799,198

U01 · FY2018 · HL

NIDA Clinical Trials Network: New York Node$16,012,181

UG1 · FY2023 · DA

The Ischemia Trial - CCC$13,681,446

U01 · FY2015 · HL

The Ischemia Trial - CCC$13,546,604

U01 · FY2014 · HL

EPPIC-NET DCC$13,303,854

U24 · FY2019 · NS

NIDA Clinical Trials Network: New York Node$12,351,705

UG1 · FY2021 · DA

NIDA Clinical Trials Network: New York Node$12,250,844

UG1 · FY2022 · DA

Intermediate-sized Expanded Access Protocol for CNM-Au8 in Amyotrophic Lateral Sclerosis (ALS).$11,639,047

U01 · FY2025 · NS

The Ischemia Trial - CCC$11,262,237

U01 · FY2012 · HL